Blog Coverage: Endocyte to Present Posters on its Lead Clinical Stage Assets at the ASCO Annual Meeting

Upcoming AWS Coverage on Jazz Pharma Post-Earnings Results

LONDON, UK / ACCESSWIRE / May 31, 2017 / Active Wall St. blog coverage looks at the headline from Endocyte, Inc. (NASDAQ: ECYT) as the Company, a leader in developing targeted small molecule drug conjugates (SMDCs), announced that two posters will be presented on its lead, clinical-stage assets, EC1456 and EC1169, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting being held between June 02-06, 2017, in Chicago. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Endocyte’s competitors within the Biotechnology space, Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), announced May 09, 2017, its financial results for Q1 2017 and also updated financial guidance for 2017. AWS will be initiating a research report on Jazz Pharma in the coming days.

Today, AWS is promoting its blog coverage on ECYT; touching on JAZZ. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

What is EC1456

Endocyte’s is focusing on the development of EC1456, an investigational, proprietary, injectable SMDC consisting of folate (vitamin B9) linked to a potent cytotoxic agent, tubulysin B hydrazide (TubBH). TubBH is a member of the tubulysin class of anti-neoplastic agents that inhibits the polymerization of tubulin into microtubules, a critical component during cell division.

The Company has initiated EC1456 to evaluate patients in a phase-1 study with advanced solid tumors (Part A) and FR-positive for non-small cell lung cancer (NSCLC) (Part B). The Company has also initiated a phase-1 exploratory study in patients with ovarian cancer undergoing surgery. EC1456 is the first SMDC with TubBH to enter clinical trials.

Patients included in the expansion phase of this trial are expected to receive first-line chemotherapy and may also be treated with anti-PD-1 therapy. The presentation includes data for 87 Part A treated patients with advanced solid tumors and 6 Part B treated patients with FR-positive NSCLC as of the data cutoff on May 18, 2017. Preliminary data from the Company’s first patient enrolled in the EC1456 ovarian surgical study, EC1456-02, will also be presented.

About EC1169

Apart from EC1456, Endocyte is also working on the development of companion imaging agents. EC1169 is an investigational therapeutic SMDC constructed of a high affinity prostate specific membrane antigen (PSMA)-targeting ligand conjugated through a bioreleasable linker system to a potent microtubule inhibitor, TubBH.

Patient’s PSMA-status is determined using the investigational companion imaging agent, EC0652 to identify the presence of prostate-specific membrane antigen. EC1169 is currently being evaluated in a phase-1 study in patients with metastatic castration-resistant prostate cancer (mCRPC). The primary endpoint of this expansion phase is radiographic progression-free survival (rPFS), with a target of 5 months for taxane-naïve mCRPC patients and 3 months for taxane-exposed mCRPC patients. Secondary endpoints, which will provide earlier insight into drug activity, include overall response rates as measured by response evaluation criteria in solid tumors (RECIST) and prostate-specific antigen (PSA).

The Company will provide an update for EC1169-01, a two-part phase-1 dose escalation (Part A) and expansion (Part B) study in patients with mCRPC. The presentation includes data for the expansion phase (Part B) for 24 taxane-exposed mCRPC patients and 16 taxane-naïve mCRPC patients as of the data cutoff on May 15, 2017.

Stock Performance

On Tuesday, May 30, 2017, the stock closed the trading session at $2.73, jumping 10.53% from its previous closing price of $2.47. A total volume of 629.77 thousand shares have exchanged hands, which was higher than the 3-month average volume of 368.26 thousand shares. Endocyte’s stock price soared 18.70% in the last month and 33.17% in the past three months. The stock currently has a market cap of $115.07 million.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 464525